Alexion's eculizumab succeeds in Phase III

Alexion says that its therapy for a rare form of hemolytic anemia, eculizumab, proved successful in a 52-week late stage trial. Researchers said the 97 patients in the study demonstrated a reduced level of fatigue and a reduction in red blood destruction. Alexion says it is also expanding access to the therapy for patients with the disease.

- check out this press release on the data
- here's the AP report

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.